Original BioMedicals Co., Ltd. (6483.TWO)

15.55 -0.25 (-1.58%) As of 11:03AM CST. Market open.

Original BioMedicals Co., Ltd.

6F., No.415
Sec. 2, Tiding Blvd. Neihu Dist.
Taipei 74147
Taiwan
886 2 2658 8599
https://www.i-obm.com/English_Version/index.aspx

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Duncan Chen MS	Chairman & CTO	N/A	N/A	N/A
Dr. Cliff C. Wang Ph.D.	Chief Executive Officer and Director	N/A	N/A	N/A
Selena Lin	Chief Financial Officer	N/A	N/A	N/A
Hsiao-Pao Yen	Chief Operating Officer and Director	N/A	N/A	N/A
Ms. Cecilia Hung	Director of Development	N/A	N/A	N/A
Dr. Alan Liss Ph.D.	Senior Vice President	N/A	N/A	1948
Gan Xiao Ping	Head of Clinical Research Department	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Original BioMedicals Co., Ltd., a biotechnology company, chemical entities to solve unmet medical needs in Taiwan. It develops (A01) Radprotect, a pre-clinical product to protects against radiation exposer; (A02) CCM-Ami, which protects normal tissues from the toxic effects of chemotherapeutic agents and ionizing radiation; and ((P01)GLP-1 CCM for the treatment of type 2 diabetes. The company was founded in 2011 and is based in Taipei, Taiwan.

Corporate governance

Original BioMedicals Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.